{"id":"sotalol","brandName":"Betapace","genericName":"sotalol","companyId":"bayer","companyName":"Bayer","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":0,"mechanism":{"target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Potassium voltage-gated channel subfamily H member 2"},"administration":{"route":"Oral"},"safety":{"boxedWarnings":["WARNING: LIFE-THREATENING PROARRHYTHMIA To minimize the risk of drug-induced arrhythmia, initiate or reinitiate oral sotalol in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring. Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation. If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug. Calculate creatinine clearance to determine appropriate dosing [see Dosage and Administration ( 2.5 )] . WARNING: LIFE-THREATENING PROARRHYTHMIA See full prescribing information for complete boxed warning. Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation. If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug. Initiate or reinitiate in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring. Adjust the dosing interval based on creatinine clearance."],"safetySignals":[{"date":"","signal":"ATRIAL FIBRILLATION","source":"FDA FAERS","actionTaken":"1180 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"946 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"916 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"870 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"737 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"722 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"694 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"656 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"628 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"580 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Fatigue","drugRate":"20%","severity":"common","organSystem":""},{"effect":"Bradycardia","drugRate":"13%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"16%","severity":"common","organSystem":""},{"effect":"Dyspnea","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Nausea/Vomiting","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Weakness","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Hyperhidrosis","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"2%","severity":"common","organSystem":""}],"contraindications":["Anaphylaxis","Asthma","Bronchospasm","Cardiogenic shock","Complete atrioventricular block","Congenital long QT syndrome","Decompensated cardiac failure","Diabetes mellitus","Hypokalemia","Hypomagnesemia","Impaired renal function disorder","Low blood pressure","Pregnancy, function","Prolonged QT interval","Second degree atrioventricular block","Sick sinus syndrome","Sinus bradycardia","Torsades de pointes"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Torsade de Pointes","drugRate":"","severity":"serious"},{"effect":"Ventricular Tachycardia/Ventricular Fibrillation (VT/VF)","drugRate":"","severity":"serious"},{"effect":"Proarrhythmia","drugRate":"2.2%","severity":"serious"},{"effect":"QT interval prolongation","drugRate":"1.4%","severity":"serious"},{"effect":"Pulmonary edema","drugRate":"","severity":"serious"},{"effect":"Thrombocytopenia","drugRate":"","severity":"serious"},{"effect":"Leukopenia","drugRate":"","severity":"serious"},{"effect":"Eosinophilia","drugRate":"","severity":"serious"}]},"trials":["NCT02303639","NCT00035451","NCT02294955","NCT00007605","NCT01316952","NCT03531502","NCT05364866","NCT04767061","NCT02439658","NCT03437356","NCT06096337","NCT02389218","NCT05034432","NCT01798277","NCT00578617","NCT00000464","NCT00523978","NCT00911508","NCT05514860","NCT04208997","NCT03228823","NCT03845010","NCT00000531","NCT02459574","NCT07447297","NCT00000556","NCT03799536","NCT01709682","NCT02114528","NCT00540787","NCT07445334","NCT02347111","NCT02624765","NCT01856075","NCT02145546","NCT01477983","NCT01505296","NCT00000518","NCT06669299","NCT02241252","NCT02153437","NCT00392106","NCT02830360","NCT04991896","NCT01877473","NCT00589303","NCT06322017","NCT01780311","NCT05279833","NCT00257959"],"indications":{"approved":[{"name":"Atrial fibrillation","diseaseId":"atrial-fibrillation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Life-Threatening Ventricular Tachycardia","diseaseId":"life-threatening-ventricular-tachycardia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT02303639","phase":"Phase 4","title":"Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias. A Prospective, Randomized Multicentre Study.","status":"UNKNOWN","sponsor":"Central Finland Hospital District","isPivotal":false,"enrollment":120,"indication":"Myocardial Infarction, Ventricular Tachyarrhythmia","completionDate":"2018-06"},{"nctId":"NCT00035451","phase":"Phase 3","title":"Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.","status":"COMPLETED","sponsor":"Forest Laboratories","isPivotal":true,"enrollment":658,"indication":"Atrial Fibrillation","completionDate":"2003-06"},{"nctId":"NCT02294955","phase":"NA","title":"Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation - a Randomized Multicentre Study Comparing Atrial Fibrillation Ablation Strategy With Optimized Conventional Pharmacolog","status":"UNKNOWN","sponsor":"Uppsala University Hospital","isPivotal":false,"enrollment":152,"indication":"Atrial Fibrillation, Quality of Life","completionDate":"2018-09"},{"nctId":"NCT00007605","phase":"Phase 3","title":"CSP #399 - The Effects of Antiarrhythmic Therapy in Maintaining Stability of Sinus Rhythm in Atrial Fibrillation","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","isPivotal":true,"enrollment":706,"indication":"Atrial Fibrillation, Cerebrovascular Accident","completionDate":"2003-12"},{"nctId":"NCT01316952","phase":"N/A","title":"A Nested Case-control Study of the Association Between Coreg IR and Coreg CR and Hypersensitivity Reactions: Anaphylactic Reaction/Angioedema-Updated Analysis","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":1,"indication":"Hypersensitivity","completionDate":"2011-03"},{"nctId":"NCT03531502","phase":"NA","title":"Initial Management of Patients Receiving a Single Shock (IMPRESS)","status":"TERMINATED","sponsor":"Saint Luke's Health System","isPivotal":false,"enrollment":30,"indication":"Ventricular Tachycardia","completionDate":"2023-04-04"},{"nctId":"NCT05364866","phase":"N/A","title":"Cryoballoon Ablation Versus Medical Therapy in Patients With Atrial Fibrillation and Heart Failure With Different Ejection Fraction Categories","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","isPivotal":false,"enrollment":200,"indication":"Cardiovascular Diseases","completionDate":"2024-12-31"},{"nctId":"NCT04767061","phase":"Phase 4","title":"N-of-1 Trials for Deprescribing Beta-blockers in HFpEF","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","isPivotal":false,"enrollment":9,"indication":"Heart Failure, Heart Failure, Diastolic","completionDate":"2023-04-28"},{"nctId":"NCT02439658","phase":"N/A","title":"Genetics of QT Prolongation With Antiarrhythmics","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":1000,"indication":"Long QT Syndrome, Drug Toxicity","completionDate":"2023-04-30"},{"nctId":"NCT03437356","phase":"NA","title":"Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Persistent Atrial Fibrillation: a Prospective Multi-centre Randomized Controlled Clinical Study","status":"COMPLETED","sponsor":"AZ Sint-Jan AV","isPivotal":false,"enrollment":210,"indication":"Atrial Fibrillation","completionDate":"2022-06-30"},{"nctId":"NCT06096337","phase":"NA","title":"A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","isPivotal":false,"enrollment":484,"indication":"Persistent Atrial Fibrillation","completionDate":"2028-02-04"},{"nctId":"NCT02389218","phase":"Phase 4","title":"A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation","status":"COMPLETED","sponsor":"University Hospital, Ghent","isPivotal":false,"enrollment":13,"indication":"Atrial Fibrillation","completionDate":"2020-05-14"},{"nctId":"NCT05034432","phase":"Phase 4","title":"Prophylactic Intra-Operative Ventricular Arrhythmia Ablation in High-Risk LVAD Candidates (PIVATAL)","status":"RECRUITING","sponsor":"University of Rochester","isPivotal":false,"enrollment":100,"indication":"Arrythmia, Cardiomyopathies","completionDate":"2027-06-30"},{"nctId":"NCT01798277","phase":"Phase 3","title":"Ablation Versus Medical Therapy in Patients With Coronary Artery Disease and Sustained Ventricular Tachycardia Randomized Trial (VeTAMed)","status":"WITHDRAWN","sponsor":"Newmarket Electrophysiology Research Group Inc","isPivotal":true,"enrollment":0,"indication":"Ventricular Tachycardia, Coronary Artery Disease","completionDate":"2015-12"},{"nctId":"NCT00578617","phase":"NA","title":"Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation - Pilot Trial","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":60,"indication":"Atrial Fibrillation, Arrhythmia","completionDate":"2010-06"},{"nctId":"NCT00000464","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"University of Washington","isPivotal":true,"enrollment":0,"indication":"Arrhythmia, Cardiovascular Diseases","completionDate":""},{"nctId":"NCT00523978","phase":"Phase 3","title":"A Randomized, Controlled Clinical Trial of Catheter Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation.","status":"COMPLETED","sponsor":"Medtronic Cardiac Rhythm and Heart Failure","isPivotal":true,"enrollment":245,"indication":"Paroxysmal Atrial Fibrillation","completionDate":"2011-07"},{"nctId":"NCT00911508","phase":"NA","title":"Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":2204,"indication":"Atrial Fibrillation, Arrhythmia","completionDate":"2017-12-31"},{"nctId":"NCT05514860","phase":"NA","title":"The Impact of \"First-Line\" Rhythm Therapy on AF Progression","status":"UNKNOWN","sponsor":"University of British Columbia","isPivotal":false,"enrollment":303,"indication":"Atrial Fibrillation","completionDate":"2022-11"},{"nctId":"NCT04208997","phase":"Phase 3","title":"Continuation of Antiarrhythmics Following caThEteR Ablation for Ventricular Tachycardia (AFTER-VT) Trial: A Pilot Randomized Clinical Trial","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","isPivotal":true,"enrollment":5,"indication":"Tachycardia, Ventricular, Catheter Ablation","completionDate":"2021-06-30"},{"nctId":"NCT03228823","phase":"Phase 4","title":"Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS): A Pilot Study","status":"UNKNOWN","sponsor":"Hunter Holmes Mcguire Veteran Affairs Medical Center","isPivotal":false,"enrollment":5,"indication":"Ventricular Premature Beats, Contractions, or Systoles, Cardiomyopathies","completionDate":"2021-08-31"},{"nctId":"NCT03845010","phase":"NA","title":"Elimination of Ventricular Premature Beats With CaTheter Ablation Versus OPtImal Anti-arrhythmic Drug Treatment","status":"COMPLETED","sponsor":"Maatschap Cardiologie Zwolle","isPivotal":false,"enrollment":22,"indication":"Ventricular Premature Beats","completionDate":"2023-01-17"},{"nctId":"NCT00000531","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","isPivotal":true,"enrollment":0,"indication":"Arrhythmia, Cardiovascular Diseases","completionDate":"2002-08"},{"nctId":"NCT02459574","phase":"NA","title":"Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation","status":"COMPLETED","sponsor":"Imperial College London","isPivotal":false,"enrollment":321,"indication":"Heart Failure, Recurrent Atrial Fibrillation","completionDate":"2018-11-27"},{"nctId":"NCT07447297","phase":"NA","title":"Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation","status":"RECRUITING","sponsor":"Samsung Medical Center","isPivotal":false,"enrollment":520,"indication":"Atrial Fibrillation (AF), Diseases of the Circulatory System","completionDate":"2029-12-31"},{"nctId":"NCT00000556","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","isPivotal":true,"enrollment":0,"indication":"Arrhythmia, Atrial Fibrillation","completionDate":"2002-09"},{"nctId":"NCT03799536","phase":"Phase 1","title":"Open-label, Randomized, Crossover, Two-period, Two-sequence Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex®, Tablets, 160 mg (BRISTOL-MYERS SQUIBB GmbH & ","status":"COMPLETED","sponsor":"Pharmtechnology LLC","isPivotal":false,"enrollment":36,"indication":"Bioequivalence","completionDate":"2019-02-11"},{"nctId":"NCT01709682","phase":"Phase 2","title":"Progression of Atrial Fibrillation After a Failed Initial Ablation Procedure in Patients With Paroxysmal Atrial Fibrillation: A Randomized Comparison of the Drug Therapy Versus Re-Ablation","status":"COMPLETED","sponsor":"Meshalkin Research Institute of Pathology of Circulation","isPivotal":false,"enrollment":154,"indication":"Paroxysmal Atrial Fibrillation, Failed First Radiofrequency Ablation Procedure","completionDate":"2012-08"},{"nctId":"NCT02114528","phase":"Phase 4","title":"Antiarrhythmic Therapy Versus Catheter Ablation as First Line Treatment for AICD Shock Prevention: A Randomized Vanguard Pilot Trial","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","isPivotal":false,"enrollment":40,"indication":"Ventricular Tachycardia, Ventricular Arrhythmia","completionDate":"2015-11"},{"nctId":"NCT00540787","phase":"Phase 4","title":"A Randomized Comparison of the Efficacy of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation for the Maintenance of Sinus Rhythm In Patients With Paroxysmal Atrial Fibrillation","status":"COMPLETED","sponsor":"Biosense Webster, Inc.","isPivotal":false,"enrollment":112,"indication":"Paroxysmal Atrial Fibrillation","completionDate":"2006-06-01"},{"nctId":"NCT07445334","phase":"NA","title":"Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (CAAD-PVC): A Randomised Controlled Trial Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Western Sydney Local Health District","isPivotal":false,"enrollment":40,"indication":"Premature Ventricular Complexes, Premature Ventricular Contraction (PVC)","completionDate":"2028-03-01"},{"nctId":"NCT02347111","phase":"Phase 4","title":"A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs","status":"RECRUITING","sponsor":"University of Illinois at Chicago","isPivotal":false,"enrollment":162,"indication":"Atrial Fibrillation","completionDate":"2026-06-30"},{"nctId":"NCT02624765","phase":"Phase 3","title":"FAST RCT: Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy","status":"COMPLETED","sponsor":"Edgar Jaeggi","isPivotal":true,"enrollment":105,"indication":"Fetal Atrial Flutter Without Hydrops, Fetal Supraventricular Tachycardia Without Hydrops","completionDate":"2024-03-31"},{"nctId":"NCT01856075","phase":"N/A","title":"Relative Effectiveness of Dronedarone vs. Other Treatments of Atrial Fibrillation","status":"COMPLETED","sponsor":"La-ser Europe Limited","isPivotal":false,"enrollment":1015,"indication":"Atrial Fibrillation","completionDate":"2015-08"},{"nctId":"NCT02145546","phase":"Phase 4","title":"Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","isPivotal":false,"enrollment":600,"indication":"Atrial Fibrillation","completionDate":"2017-05"},{"nctId":"NCT01477983","phase":"Phase 4","title":"Kansai Plus Atrial Fibrillation Trial; UNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate Trial; Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fib","status":"COMPLETED","sponsor":"Kyoto University, Graduate School of Medicine","isPivotal":false,"enrollment":2113,"indication":"Atrial Fibrillation","completionDate":"2017-07"},{"nctId":"NCT01505296","phase":"Phase 4","title":"Randomized Comparison of Catheter Ablation Versus Anti-arrhythmic Drug Therapy in Patients With Recently Diagnosed Paroxysmal Atrial Fibrillation as Assessed by a Continuous Implantable Monitor","status":"WITHDRAWN","sponsor":"Valley Health System","isPivotal":false,"enrollment":0,"indication":"Atrial Fibrillation","completionDate":"2014-01"},{"nctId":"NCT00000518","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"University of Utah","isPivotal":true,"enrollment":0,"indication":"Arrhythmia, Cardiovascular Diseases","completionDate":"1992-12"},{"nctId":"NCT06669299","phase":"NA","title":"The Value of Late Non-Invasive Programmed Stimulation (NIPS) in the Setting of Ventricular Tachycardia (VT) Ablation to Guide the Subsequent VT Therapeutic Strategies: a Prospective Randomized Multice","status":"RECRUITING","sponsor":"IRCCS Ospedale San Raffaele","isPivotal":false,"enrollment":51,"indication":"Ventricular Tachycardia (VT)","completionDate":"2027-12"},{"nctId":"NCT02241252","phase":"NA","title":"Clinical Validation of an iPhone ECG System, QT Substudy","status":"COMPLETED","sponsor":"University of Oklahoma","isPivotal":false,"enrollment":29,"indication":"Cardiac Arrhythmia, Qt Interval, Variation in","completionDate":"2015-05"},{"nctId":"NCT02153437","phase":"Phase 1","title":"A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":7,"indication":"Atrial Fibrillation","completionDate":"2016-10-20"},{"nctId":"NCT00392106","phase":"Phase 3","title":"Study of Focused Circumferential UltraSound for the Treatment of Atrial Fibrillation","status":"SUSPENDED","sponsor":"ProRhythm, Inc.","isPivotal":true,"enrollment":240,"indication":"Atrial Fibrillation","completionDate":"2011-06"},{"nctId":"NCT02830360","phase":"Phase 4","title":"Ventricular Tachycardia Antiarrhythmics or AblatioN In Structural Heart Disease 2","status":"COMPLETED","sponsor":"John Sapp","isPivotal":false,"enrollment":416,"indication":"Ventricular Tachycardia (VT)","completionDate":"2024-06-30"},{"nctId":"NCT04991896","phase":"N/A","title":"Acute Management of Paroxysmal Atrial Fibrillation With Beta Blockers Plus Intravenous Flecainide: a Real-world Chios Registry (BETAFLEC-CHIOS)","status":"COMPLETED","sponsor":"AHEPA University Hospital","isPivotal":false,"enrollment":81,"indication":"Atrial Fibrillation, Arrhythmias, Cardiac","completionDate":"2021-06-30"},{"nctId":"NCT01877473","phase":"Phase 4","title":"","status":"WITHDRAWN","sponsor":"Valley Health System","isPivotal":false,"enrollment":0,"indication":"Persistent Atrial Fibrillation","completionDate":"2013-09"},{"nctId":"NCT00589303","phase":"Phase 3","title":"Pacing and AV Node Ablation Compared to Drug Therapy in Symptomatic Elderly Patients With Atrial Fibrillation Clinical Trial (PACIFIC) - Pilot Study","status":"TERMINATED","sponsor":"Mayo Clinic","isPivotal":true,"enrollment":27,"indication":"Atrial Fibrillation, Heart Failure","completionDate":"2011-07"},{"nctId":"NCT06322017","phase":"NA","title":"Prospective Multicenter Randomized and Controlled Study Evaluating the Benefit of Early Pulmonary Vein Isolation Compared to Usual Treatment in Patients Aged Over 75 Years and Presenting With Atrial F","status":"RECRUITING","sponsor":"Nantes University Hospital","isPivotal":false,"enrollment":294,"indication":"Atrial Fibrillation","completionDate":"2030-04-09"},{"nctId":"NCT01780311","phase":"Phase 4","title":"","status":"UNKNOWN","sponsor":"Ospedale San Donato","isPivotal":false,"enrollment":0,"indication":"Ventricular Tachycardia, Ventricular Premature Complexes","completionDate":""},{"nctId":"NCT05279833","phase":"N/A","title":"SLR/NMA of Multaq® vs Sotalol to Assess for Safety in Patients With Atrial Fibrillation (AFib)","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":87810,"indication":"Atrial Fibrillation","completionDate":"2022-03-31"},{"nctId":"NCT00257959","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Connolly, Stuart, M.D.","isPivotal":false,"enrollment":400,"indication":"Ventricular Tachycardia","completionDate":"2004-10"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1245/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$45","description":"SOTALOL 120 MG TABLET","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-11-22T00:00:00.000Z","mah":"LEGACY PHARMA","brand_name_local":null,"application_number":"NDA019865"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-05-13T00:00:00.000Z","mah":"AIPING PHARM INC","brand_name_local":null,"application_number":"ANDA075500"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-09-04T00:00:00.000Z","mah":"TEVA","brand_name_local":null,"application_number":"ANDA075429"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-11-02T00:00:00.000Z","mah":"REGCON HOLDINGS","brand_name_local":null,"application_number":"ANDA207429"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-04-30T00:00:00.000Z","mah":"AUROBINDO PHARMA USA","brand_name_local":null,"application_number":"ANDA077616"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=sotalol","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:19:05.367765+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:19:11.266676+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:19:04.491166+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=sotalol","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:19:11.594573+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:01.247247+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: LIFE-THREATENING PROARRHYTHMIA To minimize the risk of drug-induced arrhythmia, initiate or reinitiate oral sotalol in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring. Sotalol can cause life-threatening ventricular tachycardia associated with QT interval prolongation. If the QT interval prolongs to 500 msec or greater, reduce the dose, lengthen the dosing interval, or discontinue the drug. Calculate creatinine clearance to determine appro","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:01.247282+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:19:13.249754+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL471/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:19:12.446640+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA075563","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:01.247287+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:19:16.542610+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL471"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}